AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39066382
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (Priorix and M-M-RII)
Trial: 39066557
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug use (Control)
Trial: 39066638
Drug: Spironolactone 100
RxNorm normalized name: spironolactone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 100 mg/day for 16 weeks
Trial: 39066638
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate 100 mg/day for 16 weeks
Trial: 39066638
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate 100 mg/day
Trial: 39066746
Drug: Invisalign First
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invisalign First Phase I treatment (CAT group)
Trial: 39066962
Drug: Tumor Necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Necrosis Factor inhibitors (TNFi)
Trial: 39067509
Drug: Azelastine HCl
RxNorm normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine HCl 0.15% nasal spray (2 sprays per nostril)
Trial: 39067618
Drug: RAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitors prescribed at discharge
Trial: 39067870
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carvedilol and VBL (group C)
Trial: 39067870
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (Combination)
Trial: 39067873
Drug: Ipilimumab 1
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 1 mg/kg intravenously every 6 weeks plus nivolumab 240 mg intravenously every 2 weeks until disease progression or other criteria met.
Trial: 39067876
Drug: Join4Joy approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Join4Joy approach in physical activity programmes, consisting of twelve, 1-hour weekly sessions of structured, supervised, group-based physical activity.
Trial: 39068435
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection (n=26)
Trial: 39068435
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (neurodynamic exercise, steroid injection, advice)
Trial: 39068937
Drug: Active weekly
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active weekly fever screening plus monthly RDT testing and treatment (group 3)
Trial: 39068937
Drug: Active weekly
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active weekly fever screening (group 2)
Trial: 39068937
Drug: Active monthly
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active monthly RDT testing and treatment (group 3)
Trial: 39068945
Drug: Site-specific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Site-specific therapy guided by a 90-gene expression assay
Trial: 39068945
Drug: Empirical chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical chemotherapy
Trial: 39069087
Drug: Proton or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton or photon beam therapy
Trial: 39069096
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of original wild-type BNT162b2
Trial: 39069259
Drug: Daily phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily phosphate measurements
Trial: 39069269
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg C15:0 daily for 12 weeks
Trial: 39069599
Drug: Ultra-rapid aspart
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-rapid aspart (insulin type)
Trial: 39069599
Drug: Aspart (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspart (insulin type)
Trial: 39069967
Drug: Gefapixant 180
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 180 mg
Trial: 39070019
Drug: 5-min daily
RxNorm normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5-min daily meditation practice
Trial: 39070019
Drug: 15-min daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 15-min daily meditation practice
Trial: 39070044
Drug: Increased predicted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased predicted anti-spike immunoglobulin G titer
Trial: 39070853
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg oral tablet
Trial: 39071916
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg L and 2 mg Z softgel (Carotenoid Group)
Trial: 39072039
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy initiation and duration
Trial: 39072042
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) with dihydroartemisinin-piperaquine+single-low dose primaquine
Trial: 39073577
Drug: SAR monotherapy
RxNorm normalized name: SAR-125844
DrugBank: SAR-125844 (DB15382)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR monotherapy
Trial: 39073796
Drug: Consult for
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consult for Addiction Treatment and Care in Hospitals (CATCH) program
Trial: 39073799
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg intravenous every 3 weeks for up to nine treatment cycles
Trial: 39073799
Drug: Baseline scores
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline scores (before treatment)
Trial: 39073823
Drug: Invitation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services.
Trial: 39073823
Drug: Invitation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among Black individuals.
Trial: 39073823
Drug: Invitation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among White individuals.
Trial: 39074931
Drug: Niraparib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (200 mg) and Etoposide (50 mg)
Trial: 39075274
Drug: Difamilast 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difamilast 0.3% ointment applied twice daily
Trial: 39075274
Drug: Difamilast 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difamilast 0.3% or 1% ointment applied based on existing symptoms
Trial: 39075354
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no vasopressor administration)
Trial: 39075506
Drug: Healthcare worker
RxNorm normalized name: TRICLOSAN .01 g in 10 mL TOPICAL LIQUID [Zep Professional Healthcare Worker]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare worker HTN and CVD care training plus long-term practice facilitation, electronic health record (EHR) documentation of key indicators and use of reminders, and use of treatment partners to provide social support.
Trial: 39075587
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus vitamin C
Trial: 39075925
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (Gla-300)
Trial: 39076099
Drug: Trastuzumab biosimilar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab biosimilar (AryoTrust) administered every 3 weeks for nine cycles
Trial: 39076483
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TCFA and minimal lumen area (MLA)
Trial: 39076569
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic preconditioning (RIPC) applied on the left upper limb twice daily, starting three days before DCB implantation.
Trial: 39076593
Drug: SHR-1905 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1905 (50, 100, 200, 400, and 600 mg)
Trial: 39078582
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream applied twice daily for up to 52 weeks
Trial: 39078582
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream
Trial: 39079614
Drug: FBT+ER (Family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBT+ER (Family-based treatment with emotion regulation)
Trial: 39079614
Drug: FBT (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FBT (Standard Family-based treatment)
Trial: 39079894
Drug: Active Conventional
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Conventional Treatment (ACT)
Trial: 39079894
Drug: Biological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological treatments (including certolizumab pegol and tocilizumab)
Trial: 39079926
Drug: Integrated evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated evidence-based physical therapy (I-EPT) with mindfulness-based interventions
Trial: 39080181
Drug: Stapokibart 600
RxNorm normalized name: Stapokibart
DrugBank: Stapokibart (DB18990)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stapokibart 600 mg loading dose, then 300 mg every 2 weeks for 52 weeks
Trial: 39080350
Drug: Dactinomycin and
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dactinomycin and Vincristine (AV) chemotherapy
Trial: 39080350
Drug: Dactinomycin and
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dactinomycin and Vincristine (AV) chemotherapy for bilateral stage I patients
Trial: 39080380
Drug: Cuffs Collapsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuffs Collapsed group (CC group, n=30)
Trial: 39080698
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management (early mobilization under physiotherapy and analgesics)
Trial: 39081141
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 12 sessions (2 sessions per week, 1 hour each, over 6 weeks)
Trial: 39081682
Drug: No-added-sugar ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-added-sugar ice cream
Trial: 39081682
Drug: Conventional ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ice cream
Trial: 39081738
Drug: Lumasiran (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumasiran (36 months of treatment)
Trial: 39081738
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 months of lumasiran treatment)
Trial: 39355649
Drug: Lumasiran treatment
RxNorm normalized name: lumasiran
DrugBank: Lumasiran (DB15935)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lumasiran treatment
Trial: 39081763
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly semaglutide
Trial: 39082399
Drug: Sacubitril/valsartan (ARNI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (ARNI) therapy
Trial: 39082406
Drug: Cardiovascular polypill
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardiovascular polypill (2 Polycaps taken orally once a day for 12 months, containing aspirin 100mg, simvastatin 20mg, hydrochlorothiazide 12.5mg, ramipril 5mg, and atenolol 50mg)
Trial: 39082406
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (standard secondary prevention therapy)
Trial: 39082803
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of meropenem
Trial: 39082803
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion (II) of meropenem
Trial: 39083052
Drug: Pregnancy pilates-assisted
RxNorm normalized name: PREGNANCY TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnancy pilates-assisted birth preparation training (twice a week for 8 weeks)
Trial: 39083052
Drug: Pregnancy pilates-assisted
RxNorm normalized name: PREGNANCY TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnancy pilates-assisted birth preparation training
Trial: 39083105
Drug: Intraventricular radioimmunotherapy
RxNorm normalized name: cerliponase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of radiolabeled antibody
Trial: 39083099
Drug: VACStent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACStent treatment for anastomotic leak (AL) without stoma placement
Trial: 39083099
Drug: VACStent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACStent treatment for anastomotic leak (AL) after stoma placement
Trial: 39083185
Drug: Narrow-diameter implants
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-diameter implants with immediate provisionalization
Trial: 39083288
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg every 16 weeks
Trial: 39083323
Drug: HER2-targeted PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER2-targeted PET/CT imaging before anti-HER2 therapy
Trial: 39206189
Drug: AS01-adjuvanted vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS01-adjuvanted vaccine
Trial: 39083724
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) 10 mg/kg once on days 1 and 8 every 3 weeks
Trial: 39083792
Drug: Telerehabilitation (TR)
RxNorm normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation (TR) administered via a web-based application, 1-hour sessions weekly for 4 weeks
Trial: 39083792
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) with home exercises provided on paper, 1-hour sessions weekly for 4 weeks
Trial: 39083792
Drug: Clinic+TR group
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic+TR group with in-person sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Trial: 39083792
Drug: TR-only group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-only group with virtual sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Trial: 39084177
Drug: Partial clinical
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial clinical remission (pCR) defined as stimulated C-peptide >300 pmol/l
Trial: 39084177
Drug: Partial clinical
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial clinical remission (pCR) defined as insulin dose-adjusted HbA1c ≤9%
Trial: 39084177
Drug: Partial clinical
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial clinical remission (pCR) defined as insulin dose <0.3 IU/kg/24 h and HbA1c ≤6.4% (46 mmol/mol)
Trial: 39084177
Drug: Partial clinical
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial clinical remission (pCR) defined as insulin dose <0.5 IU/kg/24 h and HbA1c <7% (53 mmol/mol)
Trial: 39084177
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of age, HbA1c, diastolic blood pressure, triglycerides and smoking at T1D onset
Trial: 39084177
Drug: HbA1c, triglycerides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbA1c, triglycerides and insulin dose 3-months post-diagnosis
Trial: 39084489
Drug: KT-474, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KT-474, a targeted degrader of IRAK4, ex vivo treatment of PBMCs from healthy volunteers and patients with HS.
Trial: 39084489
Drug: KT-474, ex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KT-474, ex vivo treatment of toll-like receptor-stimulated healthy donor monocytes.
Trial: 39084827
Drug: Jewel patch-wearable
RxNorm normalized name: jewel weed whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jewel patch-wearable cardioverter-defibrillator (P-WCD)
Trial: 39084863
Drug: Healthy mutation
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy mutation carriers (HMC) with elevated t-tau (>290 pg/mL)
Trial: 39084935
Drug: Random forest
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random forest algorithm for predicting PD-L1 expression and immunotherapy prognosis
Trial: 39084935
Drug: Random forest
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random forest model predicting treatment response in PD-L1 high-expression patients
Trial: 39085322
Drug: Topical solution
RxNorm normalized name: Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution of plant terpenes containing camphor, menthol, eugenol, eucalyptol, and vanillin with 15% DMSO, 1% limonene, and rosemary oil applied topically twice daily.
Trial: 39085664
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Auriculotherapy and Acupuncture (AUR-ACU)
Trial: 39085831
Drug: SMP (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMP (6 weekly sessions)
Trial: 39085831
Drug: SMP +
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMP + HBCC (6 weekly sessions)
Trial: 39085927
Drug: Multidisciplinary lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary lifestyle interventions (MLI) - 3 months of weekly 2-hour sessions on diet education, yoga, music therapy, and cognitive skills training.
Trial: 39086857
Drug: Functional fitness
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional fitness training and mastering physical literacy class twice a week with buddy peer support for 12 weeks, including reflective writing journal.
Trial: 39087355
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no valsartan treatment)
Trial: 39087734
Drug: Concurrent trauma-focused
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent trauma-focused and personality disorder treatment
Trial: 39087734
Drug: Only trauma-focused
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only trauma-focused treatment
Trial: 39087868
Drug: Amoxicillin 1000
RxNorm normalized name: amoxicillin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000 mg three times daily before meals (BM-TID)
Trial: 39087868
Drug: Amoxicillin 1000
RxNorm normalized name: amoxicillin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000 mg three times daily after meals (AM-TID)
Trial: 39087868
Drug: Amoxicillin 750
RxNorm normalized name: amoxicillin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 750 mg four times daily after meals (AM-QID)
Trial: 39088062
Drug: Pre-hospital heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital heparin administration